Tonix Pharmaceuticals Holding Corp. (TNXP)

Latest News

View all news

Sep 22, 2022

Tonix Pharmaceuticals Presents Data from Retrospective Observational Database Study on the Incidence of Multi-Site Pain Symptoms in Long COVID Patients at IASP 2022 World Congress on Pain

Sep 15, 2022

Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (Fc-Modified Anti-CD40L mAb) for the Prevention of Rejection in Allograft and Xenograft Transplantation in Animal Models at the International Congress of The Transplantation Society (TTS 2022)

Sep 6, 2022

Tonix Pharmaceuticals Announces Oral Presentations Involving TNX-1500 (Fc-Modified Anti-CD40L mAb) at the International Congress of The Transplantation Society (TTS 2022)

View all news

Investor Factsheet

View Presentation

IASP 2022 World Congress on Pain

Add to Calendar View All Events

Latest Financial Results

Q2 2022

Quarter Ended Jun 30, 2022

Earnings Release

PDF HTML

10-Q

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2021

IR Contacts

Company

Tonix Pharmaceuticals Holding Corp.
26 Main Street
Suite 101
Chatham, NJ 07928
T: 862-799-8599
investor.relations@tonixpharma.com

Investor Relations

TONIX Pharmaceuticals
investor.relations@tonixpharma.com

Transfer Agent

VStock Transfer, LLC
77 Spruce Street
Suite 201
Cedarhurst, NY 11516
T: 212-828-8436
https://www.vstocktransfer.com

Tonix is enrolling participants in a Phase 3 trial for fibromyalgia, the RESILIENT study. For more information, please visit www.resilientstudy.com or www.clinicaltrials.gov (NCT05273749).

Investor Relations

Latest News

Tonix Pharmaceuticals Presents Data from Retrospective Observational Database Study on the Incidence of Multi-Site Pain Symptoms in Long COVID Patients at IASP 2022 World Congress on Pain

Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (Fc-Modified Anti-CD40L mAb) for the Prevention of Rejection in Allograft and Xenograft Transplantation in Animal Models at the International Congress of The Transplantation Society (TTS 2022)

Tonix Pharmaceuticals Announces Oral Presentations Involving TNX-1500 (Fc-Modified Anti-CD40L mAb) at the International Congress of The Transplantation Society (TTS 2022)

Latest Presentation

Upcoming Event

Latest Financial Results

Q2 2022

Latest Annual Filing

IR Contacts

Company

Investor Relations

Transfer Agent

Investor Relations

Latest News

Tonix Pharmaceuticals Presents Data from Retrospective Observational Database Study on the Incidence of Multi-Site Pain Symptoms in Long COVID Patients at IASP 2022 World Congress on Pain

Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (Fc-Modified Anti-CD40L mAb) for the Prevention of Rejection in Allograft and Xenograft Transplantation in Animal Models at the International Congress of The Transplantation Society (TTS 2022)

Tonix Pharmaceuticals Announces Oral Presentations Involving TNX-1500 (Fc-Modified Anti-CD40L mAb) at the International Congress of The Transplantation Society (TTS 2022)

Latest Presentation

Upcoming Event

Latest Financial Results

Q2 2022

Latest Annual Filing

Report Links

Email Alerts

Stock Snapshot

IR Contacts

Company

Investor Relations

Transfer Agent